Description
Tranexamic Acid (TXA) for Pigmentation and Melasma
1. Overview:
Tranexamic acid is a synthetic derivative of the amino acid lysine. It primarily functions as an antifibrinolytic by inhibiting plasminogen activation. In dermatology, TXA is increasingly used for the treatment of melasma, post-inflammatory hyperpigmentation (PIH), and UV-induced pigmentation due to its ability to interfere with melanogenesis.
2. Mechanism of Action in Pigmentation Disorders:
- Inhibits melanocyte activation: TXA blocks the interaction between keratinocytes and melanocytes by inhibiting the plasminogen/plasmin system. This reduces the release of inflammatory mediators like arachidonic acid and prostaglandins that stimulate melanin synthesis.
- Vascular component: It reduces neovascularization in melasma by downregulating VEGF (vascular endothelial growth factor), which contributes to the improvement of dermal-type melasma.
- Reduces UV-induced pigmentation: By inhibiting plasmin, it reduces the production of melanocyte-stimulating factors after UV exposure.
3. Forms of TXA Used in Aesthetic Dermatology:
- Oral TXA:
- Dose: 250 mg twice daily for 8–12 weeks (commonly used in Asian studies).
- Often combined with topical or procedural therapies.
- Topical TXA:
- Concentration: 2–5% cream or serum.
- Often used in combination with other depigmenting agents such as niacinamide, kojic acid, or vitamin C.
- Injectable TXA (Mesotherapy or Microneedling):
- Dose: 4–6 mg/ml, injected intradermally or used with microneedling in melasma-prone areas.
4. Indications in Dermatology:
- Melasma (epidermal, dermal, or mixed types)
- PIH (especially after acne, lasers, or trauma)
- UV-induced pigmentation
- Pigmentation associated with vascularity (telangiectasia in melasma)
5. Contraindications:
- Personal or family history of thromboembolic disorders (e.g., DVT, PE, stroke, MI)
- Use of combined oral contraceptive pills (COCPs) – increased risk of thrombosis
- Active intravascular clotting disorders
- Hypersensitivity to TXA
- Severe renal impairment (due to renal excretion of the drug)
- History of seizure disorders – TXA lowers seizure threshold, especially with IV use
6. Adverse Effects:
- Oral use:
- Gastrointestinal upset (nausea, diarrhea, abdominal discomfort)
- Headache
- Menstrual irregularities
- Risk of thrombosis (rare at low doses in healthy individuals)
- Topical use:
- Mild skin irritation
- Erythema or contact dermatitis (rare)
- Injectable use:
- Mild local discomfort or erythema
- Risk of bruising
7. Clinical Results & Duration:
- Visible improvement typically within 4–8 weeks
- Best results seen with combination therapy (e.g., TXA + sunscreen + topical depigmenting agents + procedural support like microneedling or laser)
- Relapse is common if sun protection and maintenance therapy are not continued
8. Drug Interactions & Precautions:
- Avoid concurrent use with estrogens (e.g., hormonal therapy, contraceptives)
- Caution with anticoagulants or patients at risk of bleeding/clotting disorders
- Routine blood tests are not required for low-dose oral TXA in healthy patients, but it may be advisable to assess coagulation profile in at-risk individuals before starting.
9. Patient Selection Tips:
- Best suited for refractory melasma or patients who have plateaued on topical treatments alone
- Ideal for those who can commit to strict photoprotection
- Caution in patients with vascular risk factors or on hormonal treatments
10. Summary Protocol Example (Melasma Management):
- Oral TXA: 250 mg BID for 12 weeks
- Topical TXA: 3% serum daily or BID
- Microneedling: With 5 mg/ml TXA solution monthly for 3 sessions
- Combine with:
- SPF 50+ sunscreen daily
- Depigmenting agents (e.g., 4% hydroquinone at night)
- Antioxidants (vitamin C) in the morning
- Monthly or bi-monthly maintenance treatments post-clearance
Reviews
There are no reviews yet.